Last reviewed · How we verify

Anti-PD-1 monoclonal antibody

Yancheng First People's Hospital · Phase 3 active Small molecule

Anti-PD-1 monoclonal antibody is a PD-1 inhibitor Small molecule drug developed by Yancheng First People's Hospital. It is currently in Phase 3 development for Advanced or metastatic cancers (specific indications under investigation in phase 3). Also known as: PD-1 inhibitors, Tyvyt, Anti-PD-1, PD-1 inhibitor.

This drug blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.

This drug blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells. Used for Advanced or metastatic cancers (specific indications under investigation in phase 3).

At a glance

Generic nameAnti-PD-1 monoclonal antibody
Also known asPD-1 inhibitors, Tyvyt, Anti-PD-1, PD-1 inhibitor, Camrelizumab
SponsorYancheng First People's Hospital
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

PD-1 is an inhibitory receptor on T cells that cancer cells exploit to evade immune detection by engaging its ligands (PD-L1/PD-L2). By binding to and blocking PD-1, this monoclonal antibody prevents this immune evasion, restoring T cell activation, proliferation, and anti-tumor cytotoxicity. This mechanism is effective across multiple cancer types that express PD-L1.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anti-PD-1 monoclonal antibody

What is Anti-PD-1 monoclonal antibody?

Anti-PD-1 monoclonal antibody is a PD-1 inhibitor drug developed by Yancheng First People's Hospital, indicated for Advanced or metastatic cancers (specific indications under investigation in phase 3).

How does Anti-PD-1 monoclonal antibody work?

This drug blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.

What is Anti-PD-1 monoclonal antibody used for?

Anti-PD-1 monoclonal antibody is indicated for Advanced or metastatic cancers (specific indications under investigation in phase 3).

Who makes Anti-PD-1 monoclonal antibody?

Anti-PD-1 monoclonal antibody is developed by Yancheng First People's Hospital (see full Yancheng First People's Hospital pipeline at /company/yancheng-first-people-s-hospital).

Is Anti-PD-1 monoclonal antibody also known as anything else?

Anti-PD-1 monoclonal antibody is also known as PD-1 inhibitors, Tyvyt, Anti-PD-1, PD-1 inhibitor, Camrelizumab.

What drug class is Anti-PD-1 monoclonal antibody in?

Anti-PD-1 monoclonal antibody belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Anti-PD-1 monoclonal antibody in?

Anti-PD-1 monoclonal antibody is in Phase 3.

What are the side effects of Anti-PD-1 monoclonal antibody?

Common side effects of Anti-PD-1 monoclonal antibody include Fatigue, Immune-related pneumonitis, Immune-related colitis, Immune-related hepatitis, Rash, Hypothyroidism.

What does Anti-PD-1 monoclonal antibody target?

Anti-PD-1 monoclonal antibody targets PD-1 and is a PD-1 inhibitor.

Related